Reordering the pecking order: management describes the company winning on a stage where it used to be too small to play
The model's full reasoning — Q4 2022 call → NOWe need to determine if management conveys that the company has moved up a tier in its market, and that this is already producing real results, but early. The transcript discusses various products and pipeline. Key points: Libtayo was approved for first-line non-small cell lung cancer, making it only the second PD-1/PD-L1 antibody in that setting regardless of histology or PD-L1 expression. This is a significant expansion. Also, they acquired full rights to Libtayo from Sanofi. They are now competing in oncology with a broader indication. They also have aflibercept 8 mg for wet AMD and DME, which could become new standard of care. But is that a tier change? They already had EYLEA as standard of care. So that's not moving up a tier. The question is about the company now competing and winning at a level of the market that used to be above it. For example, being treated as a legitimate contender in situations that previously would have gone to bigger players. In the transcript, Len says: "We also made several important advances across our pipeline during the quarter, notably the submission of a Biologic License Application for aflibercept 8 milligrams... Additionally, we received FDA approval for Libtayo in combination with chemotherapy as a first line treatment for advanced non-small cell lung cancer, making Libtayo only the second PD-1 or PD-L1 antibody approved in this setting, regardless of the patient’s histology or PD-L1 expressions level." That is a significant achievement, but is it a tier change? They are now competing with the likes of Merck's Keytruda, which is the dominant PD-1. Being the second approved in that setting is a big deal. But does management convey that they have moved up a tier? They say "only the second" - that suggests they are now among the top players. Also, they acquired full rights to Libtayo, which was previously shared with Sanofi. That gives them more control. But the question specifically asks: "does management convey that the company has recently begun to be treated as a legitimate contender in situations, against rivals, or for business that previously would have gone to bigger, more established, or more entrenched players, and that this has already produced real results in the current period?" Look for a change in tier, already real, and early. In the transcript, there is a section about Libtayo in lung cancer.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SANG | Sangoma Technologies Corporation | Q2 2024 | 2024-02-08 | D |
| PFIE | Profire Energy, Inc. | Q1 2023 | 2023-05-13 | B |
| WD | Walker & Dunlop, Inc. | Q2 2022 | 2022-08-09 | C+ |
| PRIM | Primoris Services Corporation | Q2 2018 | 2018-08-11 | C+ |
PRIM · Q2 2018 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing exactly this tier shift in the T&D segment: after the Willbros acquisition, the group “has been able to sign new awards with customers that have been hesitant because of previous concerns about their financial viability” and has received work from “some of the largest electrical utilities in the country.” David King notes that the work “outpaces anything he has seen in his 40-plus years,” and Pete Moerbeek adds that the one-year MSA revenue alone is now $1.1 million. Management presents these wins as a direct result of Primoris’s financial strength and parent-company backing, which previously excluded the T&D business from the largest accounts. The commentary frames the development as newly enabled and still early (only one month of T&D performance), satisfying all three required elements: a clear change in competitive tier, real business already won, and contribution still incremental relative to the company’s prior scale.
SANG · Q2 2024 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management describing a shift to competing at a higher tier with sophisticated mid-market clients through bundled offerings, illustrated by a recent win with a statewide park department that larger vendors couldn't serve affordably. They explicitly note this represents a change in tier ("the type of client the bundled capabilities of Sangoma can reach ... Sangoma is well positioned to play in both the small market and more sophisticated mid-market") and that it has already produced real results ("this recent win"), while conveying it is early ("there'll be a lag before it delivers material results.
WD · Q2 2022 → YESThe question is: Does management describe that the company is NOW COMPETING AND WINNING AT A LEVEL OF THE MARKET THAT USED TO BE ABOVE IT? YES The transcript shows management explicitly describing a tier shift: from competing "predominantly with the likes of JPMorgan and Wells Fargo" to "going head-to-head with CBRE and JLL," enabled by technology investments that now allow them to "successfully compete against these much larger firms.